Aurobindo Pharma Ltd (AUROPHARMA)

Healthcare · Pharmaceuticals · NSE · Updated 1 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹1,650 ↑ 60.55% (1Y)

🎯 Key Takeaways

Aurobindo Pharma is transitioning from a mature domestic-focused API manufacturer to a globally integrated pharmaceutical company with growing emphasis on complex generics, particularly in inhalation and oncology, supported by strategic US FDA approvals and pipeline expansion. The company demonstrates improving operational efficiency and profitability, reflected in rising margins and strong shareholder confidence, though ROE remains moderate at 9.
Revenue grew 3.4% QoQ to ₹9,150 in Q1FY27.
⚠️ 1) The FDA inspection at Apitoria Pharma Unit-VI, while non-critical, requires timely resolution of procedural observations to avoid potential supply

Market Cap

₹94,937

P/E Ratio

25.8

P/B Ratio

2.51

ROE

9.8%

ROCE

12.8%

Debt/Equity

0.20

Div Yield

0.24%

Promoter

51.9%

✨ Ask AI About AUROPHARMA 📊 Interactive Charts

📖 The Story

Aurobindo Pharma is transitioning from a mature domestic-focused API manufacturer to a globally integrated pharmaceutical company with growing emphasis on complex generics, particularly in inhalation and oncology, supported by strategic US FDA approvals and pipeline expansion. The company demonstrates improving operational efficiency and profitability, reflected in rising margins and strong shareholder confidence, though ROE remains moderate at 9.8%.

📰 What's Happening

In August 2026, Aurobindo Pharma's US subsidiary Lannett launched its first generic version of GSK's Advair Diskus inhaler in the US market, marking a strategic milestone in its inhalation portfolio expansion. This follows a successful US FDA inspection at its Apitoria Pharma Unit-VI facility in Andhra Pradesh, which concluded with three procedural observations requiring follow-up. At the 39th AGM on August 27, 2026, shareholders approved all resolutions, including adoption of FY2025-26 financial statements and reappointment of directors, with overwhelming support for the ₹4 interim dividend. The company has not provided forward guidance on future deadlines or timelines for regulatory milestones.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	8,286	8,646	8,853	9,150
Operating Profit	1,249	1,309	1,274	1,394
OPM %	15.1%	15.1%	14.4%	15.2%
Net Profit	848	910	921	1,032
EPS	₹14.61	₹15.67	₹15.86	₹17.86

Aurobindo Pharma has delivered consistent top-line growth over the past four quarters, with revenue rising from ₹8,286 crore to ₹9,150 crore, while operating margins have remained stable around 15%. Net profit and EPS have increased steadily, from ₹848 crore to ₹1,032 crore and ₹14.61 to ₹17.86 respectively, indicating effective cost management and operational leverage. This upward trajectory aligns with management's focus on high-margin international markets and complex generics, supported by recent US regulatory approvals and product launches.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance on revenue, margin, or timeline expectations for upcoming product launches or regulatory submissions in the latest filing. While shareholder confidence is evident through strong AGM approvals, there is no disclosed roadmap for scaling the inhalation portfolio or entering new therapeutic areas. Investors should monitor future investor presentations or regulatory updates for indications of strategic pacing.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	58	58	58	58
Reserves	30,820	32,595	34,983	37,833
Borrowings	8,427	8,263	7,795	7,676
Total Liabilities	48,094	49,785	52,546	58,502
Fixed Assets	11,428	12,189	13,281	19,611
Investments	325	252	268	1,051
Total Assets	48,094	49,785	52,546	58,502

The balance sheet shows a stable capital structure with borrowings held steady near ₹7,700 crore over the past two years, while equity and reserves have grown from ₹32,595 crore to ₹37,833 crore, reflecting retained earnings and capital efficiency. Total assets have increased from ₹49,785 crore to ₹58,502 crore, indicating asset base expansion without significant leverage escalation. This suggests a conservative and disciplined approach to capital allocation, prioritizing organic growth and financial resilience over aggressive debt-funded expansion.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2026
Operating	+5,526
Investing	-3,459
Financing	-1,269
Net Cash Flow	+799

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	51.8%	51.8%	51.8%	51.9%
FII	14.2%	13.9%	15.2%	16.4%
DII	27.6%	27.7%	25.9%	25.1%
Public	5.3%	5.4%	5.7%	5.4%
# Shareholders	2,47,662	2,36,859	2,41,298	2,39,073

Institutional investor interest has shown mixed trends, with FII holdings declining from 16.38% in Q1FY27 to 15.24% in Q4FY26, while DII holdings rose from 27.6% to 25.87% over the same period, indicating shifting institutional preferences. Promoter holding remains stable above 51.8%, signaling no dilution or stake sale. The growing number of retail shareholders (2,39,073) reflects rising retail interest, but the decline in FII allocation may warrant monitoring of foreign investor sentiment toward global growth prospects.

⚖️ Peer Comparison — Pharmaceuticals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
SUNPHARMA	4.61 L Cr	38.1	18.7%	14.6%	0.05
DIVISLAB	2.46 L Cr	84.1	23.0%	17.4%	0.00
TORNTPHARM	1.92 L Cr	80.3	15.1%	25.7%	1.76
ZYDUSLIFE	1.18 L Cr	26.4	16.8%	16.6%	0.43
CIPLA	1.15 L Cr	34.0	13.2%	9.8%	0.01
LAURUSLABS	1.05 L Cr	95.5	20.8%	20.6%	0.45
LUPIN	99,448	17.6	27.9%	24.7%	0.26
MANKIND	98,599	48.2	13.9%	12.7%	0.38
DRREDDY	98,308	30.4	10.1%	8.4%	0.17
AUROPHARMA	94,937	25.8	12.8%	9.8%	0.20

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM ZYDUSLIFE CIPLA

⚠️ Risk Factors

1) The FDA inspection at Apitoria Pharma Unit-VI, while non-critical, requires timely resolution of procedural observations to avoid potential supply chain disruptions or delays in future approvals. 2) Heavy reliance on the US market exposes the company to regulatory and currency risks, especially as it scales complex generics. 3) Margin pressure could emerge if pricing competition intensifies in key therapeutic segments like oncology or respiratory. 4) Lack of formal forward guidance may lead to investor uncertainty despite strong execution to date.

📋 Recent Filings

🧠 Analyst's Read

Aurobindo Pharma is executing a clear strategy to transition into high-value, regulated markets with tangible progress in US inhalation and oncology pipelines, supported by solid financial momentum and shareholder confidence. The next critical watchpoint is the company's ability to scale its inhalation portfolio and manage regulatory timelines, which will determine whether this phase becomes a sustainable growth inflection or remains a niche advancement.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on AUROPHARMA

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AUROPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd